「美國吉利德科學( 77.06 , -0.89 , -1.14% )公司週二宣布，已與五家仿製藥生產商達成授權協議，允許他們在127個國家生產抗病毒藥瑞德西韋（remdesivir），不包括美國。
這五家仿製藥生產商是邁蘭製藥( 15.54 , -0.69 , -4.25% )（Mylan）、Cipla、Ferozsons Laboratories、Hetero Labs與Jubilant Lifesciences。吉利德表示，他們將生產瑞德西韋，用於在“低收入和中低收入國家，以及幾個中上收入和高收入國家”分銷，這些國家在新冠病毒大流行期間面臨衛生保健障礙。
吉利德表示，這一交易是“免專利費”的，直到世界衛生組織（WHO）宣布新冠病毒疫情不再是全球健康危機，或者“直到除瑞德西韋以外的藥物或疫苗被批准用於治療或預防新冠病毒，以較早者為準。”」
* 吉利德的股價應聲掉了3.5%，約等於少了30億美元市值。
"Gilead shares fell about 3.5%, shaving roughly $3 billion off its market cap."
"Gilead shares fell about 3.5%, shaving roughly $3 billion off its market cap."
雖然知道股價一定會跌，吉利德公司仍然這樣做了，真棒！
為了避免各國會以「強制授權」方式來生產瑞德西韋，吉利亞藥廠現在積極的先給予各國藥廠自願授權，以擴大瑞德西韋的供應量。而藥廠如果能夠提出更好的生產與授權提案，例如改為口服藥，則會被優先納入授權生產對象。
「The US drugmaker had struck similar partnerships with Indian pharma companies four years ago when it had launched its novel therapy for treatment of Hepatitis C called sofosbuvir. Granting voluntary licences is the Gilead’s preferred model in developing countries.
Legal experts are of the view that in a pandemic situation, drug companies will, as it is, prefer to make their treatment accessible rather than run the risk of countries invoking the compulsory licensing provision to allow th ..」
吉利亞藥廠授權印度藥廠為開發中國家武漢肺炎病患生產瑞德西韋。每一劑的定價，落在$59-$71美元之間。每個療程用5到11劑，所以每個病人要花 $295 and $781美元左右。
「The company plans to price the drug, which is given via intravenous infusion, at between 5,000 and 6,000 takas per vial ($59-$71/per vial), Beximco’s Chief Operating Officer Rabbur Reza told Reuters, adding a patient might need anywhere between 5 and 11 vials.
“We will only know exactly how much a patient needs once studies are complete,” Reza said. “We do expect the Bangladesh government will try to cover some of the price of the drug.”
Production will begin this month, initially for domestic use, Reza added.
Beximco’s pricing indicates a course of remdesivir treatment could cost between $295 and $781 per patient in the south Asian country depending on the severity of the case, the number of vials required and the final pricing of the drug.
The figures are a first indication of how the drug will be priced, as countries around the world struggle to control the coronavirus that has infected more than 3.5 million people worldwide.
Gilead has donated an initial batch of 1.5 million vials of to help patients in the United States, but has yet to announce its pricing.」
